PDCD1 and cancer: Immune checkpoint inhibitors (ICBs) are an important class of anti-cancer therapeutics that block the T-cell inhibitory molecules PD-1 and PD-L1, while TMB levels may reflect the potential for immunogenicity and are associated with the response to ICBs (41, 57, 58).